JP2005507666A - ２０４７を用いる、疼痛性障害を治療および診断するための方法および組成物 - Google Patents

２０４７を用いる、疼痛性障害を治療および診断するための方法および組成物 Download PDF

Info

Publication number
JP2005507666A
JP2005507666A JP2003539604A JP2003539604A JP2005507666A JP 2005507666 A JP2005507666 A JP 2005507666A JP 2003539604 A JP2003539604 A JP 2003539604A JP 2003539604 A JP2003539604 A JP 2003539604A JP 2005507666 A JP2005507666 A JP 2005507666A
Authority
JP
Japan
Prior art keywords
pain
protein
nucleic acid
expression
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003539604A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005507666A5 (https=
Inventor
インマクラダ・シロス−サンティアゴ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2005507666A publication Critical patent/JP2005507666A/ja
Publication of JP2005507666A5 publication Critical patent/JP2005507666A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2003539604A 2001-10-31 2002-10-29 ２０４７を用いる、疼痛性障害を治療および診断するための方法および組成物 Pending JP2005507666A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33500901P 2001-10-31 2001-10-31
PCT/US2002/034575 WO2003037258A2 (en) 2001-10-31 2002-10-29 Methods and compositions for the treatment and diagnosis of pain disorders using 2047

Publications (2)

Publication Number Publication Date
JP2005507666A true JP2005507666A (ja) 2005-03-24
JP2005507666A5 JP2005507666A5 (https=) 2006-01-05

Family

ID=23309847

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003539604A Pending JP2005507666A (ja) 2001-10-31 2002-10-29 ２０４７を用いる、疼痛性障害を治療および診断するための方法および組成物

Country Status (5)

Country Link
US (1) US20030091572A1 (https=)
EP (1) EP1448152A4 (https=)
JP (1) JP2005507666A (https=)
AU (1) AU2002363229A1 (https=)
WO (1) WO2003037258A2 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464820A (en) * 1993-06-22 1995-11-07 The University Hospital Specific inhibitors of tissue kallikrein
EP2301562B1 (en) * 1994-12-12 2013-04-17 Omeros Corporation Irrigation solution and method for inhibition of pain, inflammation and spasm
AU4480797A (en) * 1996-09-13 1998-04-02 Dana-Farber Cancer Institute Protease m, a novel serine protease
US7157084B2 (en) * 1997-08-21 2007-01-02 The Board Of Trustees Of The University Of Arkansas System Extracellular serine protease

Also Published As

Publication number Publication date
AU2002363229A1 (en) 2003-05-12
EP1448152A4 (en) 2006-06-07
US20030091572A1 (en) 2003-05-15
WO2003037258A2 (en) 2003-05-08
WO2003037258A3 (en) 2004-06-10
EP1448152A2 (en) 2004-08-25

Similar Documents

Publication Publication Date Title
US20060141520A1 (en) Methods for the treatment of metabolic disorders, including obesity and diabetes
US20030092041A1 (en) Novel use for muscarinic receptor M5 in the diagnosis and treatment of metabolic disorders
US20060100152A1 (en) Methods and compositions in treating pain and painful disorders using 9949, 14230, 760, 62553, 12216, 17719, 41897, 47174, 33408, 10002, 16209, 314, 636, 27410, 33260, 619, 15985, 69112, 2158, 224, 615, 44373, 95431, 22245, 2387, 16658, 55054, 16314, 1613, 1675, 9569 or 13424 molecules
WO2002012887A2 (en) Methods and compositions for the diagnosis and treatment of brown adipose cell disorders
US20030212016A1 (en) Methods and compositions for the treatment and diagnosis of body weight disorders
US20060088881A1 (en) Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 molecules
US20040077001A1 (en) Use for carboxypeptidase-A4 in the diagnosis and treatment of metabolic disorders
US20050255518A1 (en) Methods and compositions for the treatment and diagnosis of pain disorders using 46566
JP2005507666A (ja) ２０４７を用いる、疼痛性障害を治療および診断するための方法および組成物
US20030143231A1 (en) Methods and compositions for the treatment and diagnosis of pain disorders using 57749
WO2004071411A2 (en) Methods and compositions in treating pain and painful disorders using 16386, 15402, 21165, 1423, 636, 12303, 21425, 27410, 38554, 38555, 55063, 57145, 59914, 94921, 16852, 33260, 58573, 30911, 85913, 14303, 16816, 17827 or 32620
WO2004080535A2 (en) Methods and compositions for treating aids and hiv-related disorders using 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982, or 46777
US20030152970A1 (en) Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145
WO2003053364A2 (en) Methods and compositions in treating pain and painful disorders using 1465,1587, 2146, 2207, 32838, 336 and 52908
US20030087295A1 (en) Methods and compositions for the treatment and diagnosis of pain disorders using 9805
US20070179102A1 (en) Methods and compositions for the treatment and diagnosis of pain disorders using 9805, 2047, 46566, 57749, 577, 20739, 57145, 1465, 1587, 2146, 2207, 32838, 336 or 52908
US20030143610A1 (en) Methods for the treatment of metabolic disorders, including obesity and diabetes
US20030104455A1 (en) Methods and compositions for treating urological disorders using 313, 333, 5464, 18817 or 33524
US20030232044A1 (en) Use for endothelin converting enzyme 2 (ECE-2) in the diagnosis and treatment of metabolic disorders
WO2002090576A1 (en) Methods and compositions for the treatment and diagnosis of body weight disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20061128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070424